Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).

被引：0
|
作者：
Matasar, Matthew J.
Haioun, Corinne
Sancho, Juan-Manuel
Viardot, Andreas
Izquierdo, Antonia Rodriguez
Martin, Eva Maria Donato
Garcia-Sancho, Alejandro Martin
Sandoval-Sus, Jose David
Tilly, Herve
Vandenberghe, Elizabeth
Hirata, Jamie
Choudhry, Priya
Chang, Yi Meng
Musick, Lisa
McMillan, Andrew
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Grp Hosp Henri Mondor, Lymphoid Malignancies Unit, Creteil, France
[3] ICO HU Germans Trias I Pujol, Barcelona, Spain
[4] Univ Hosp Ulm, Ulm, Germany
[5] Hosp Univ 12 Octubre, Serv Hemat, Madrid, Spain
[6] Hosp Univ Dr Peset Serv Hematol, Salamanca, Spain
[7] Hosp Clin Univ Salamanca, Serv Hematol, Salamanca, Spain
[8] Mem Healthcare Inst, Moffitt Canc Ctr, Pembroke Pines, FL USA
[9] Ctr Henri Becquerel, Dept Hematol, Rouen, France
[10] Ctr Henri Becquerel, U1245, Rouen, France
[11] Univ Rouen, Rouen, France
[12] St James Hosp Canc Clin Trials Off, Dublin, Ireland
[13] Genentech Inc, South San Francisco, CA USA
[14] F Hoffmann La Roche Ltd, Mississauga, ON, Canada
[15] Nottingham Univ Hosp NHS Trust, Ctr Clin Haematol, Nottingham, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7551
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Comparative Effectiveness of Bendamustine Plus Rituximab (BR) and Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Castro, Felipe
    Surinach, Andy
    Launonen, Aino
    Thuresson, Per-Olof
    Felizzi, Federico
    BLOOD, 2020, 136
  • [22] Polatuzumab Vedotin Combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study
    Herrera, Alex F.
    Matasar, Matthew J.
    Assouline, Sarit
    Kamdar, Manali
    Mehta, Amitkumar
    Fleury, Isabelle
    Kim, Won Seog
    Kim, Tae Min
    Bosch, Francesc
    Radford, John A.
    Bu, Lilian
    Hong, Wan-Jen
    Sehn, Laurie H.
    BLOOD, 2016, 128 (22)
  • [23] Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study
    Sehn, Laurie H.
    Matasar, Matthew J.
    Flowers, Christopher R.
    Kamdar, Manali
    McMillan, Andrew K.
    Hertzberg, Mark
    Assouline, Sarit
    Kim, Tae Min
    Kim, Won Seog
    Ozcan, Muhit
    Croft, Brandon
    Hirata, Jamie
    Cheng, Ji
    Ku, Grace
    Herrera, Alex F.
    BLOOD, 2019, 134
  • [24] SUNMO: A Phase III Trial Evaluating the Efficacy and Safety of Mosunetuzumab in Combination with Polatuzumab Vedotin Versus Rituximab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
    Westin, Jason
    Olszewski, Adam J.
    Fogliatto, Laura Maria
    Kim, Won-Seog
    Shin, Ho-Jin
    Wu, Hao
    Yin, Shen
    Pham, Song
    Penuel, Elicia
    Jing, Jing
    Wei, Michael C.
    Budde, Elizabeth L.
    BLOOD, 2022, 140 : 3771 - 3772
  • [25] SUNMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin vs rituximab plus gemcitabine and oxaliplatin in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
    Westin, Jason
    Olszewski, Adam J.
    Fogliatto, Laura
    Kim, Won Seog
    Shin, Ho-Jin
    Jeon, Young-Woo
    Norasetthada, Lalita
    Pavlovsky, Astrid
    Rego, Eduardo
    Wu, Hao
    Yin, Shen
    Batlevi, Connie Lee
    Pham, Song
    Penuel, Elicia M.
    Jing, Jing
    Wei, Michael C.
    Budde, Lihua Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
    Witzig, Thomas E.
    Maddocks, Kami J.
    De Vos, Sven
    Lyons, Roger M.
    Edenfield, William Jeffery
    Sharman, Jeff Porter
    Vose, Julie
    Yimer, Habte Aragaw
    Wei, Helen
    Chan, Edward M.
    Patel, Priti
    Di Simone, Christopher
    Gandhi, Mitul
    Vaughn, Jennifer
    Kolibaba, Kathryn
    Cheson, Bruce D.
    Samaniego, Felipe
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] Polatuzumab Vedotin in Combination with Bendamustine Plus Rituximab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Our Experience
    Darcin, Tahir
    Yigenoglu, Tugce Nur
    Sahin, Derya
    Bakirtas, Mehmet
    Basci, Semih
    Merdin, Alparslan
    Yildiz, Jale
    Ulu, Bahar Uncu
    Tetik, Aysegul
    Iskender, Dicle
    Cakar, Merih Kizil
    Dal, Mehmet Sinan
    Altuntas, Fevzi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S249 - S250
  • [28] Zanubrutinib, Polatuzumab Vedotin and Rituximab (ZPR) Combination Regimen for Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma
    Zhang, Yian
    Yuan, Ling
    Zhuang, Jingli
    Wang, Zhimei
    Zhang, Xuejiao
    Wang, Weiguang
    Liu, Peng
    BLOOD, 2023, 142
  • [29] Phase III trial of bendamustine plus rituximab for relapsed or refractory diffuse large B-cell lymphoma in Japan
    Kiguchi, Toru
    Terui, Yasuhito
    Izutsu, Koji
    Kameoka, Yoshihiro
    Hidaka, Michihiro
    Kato, Harumi
    Matsumura, Itaru
    Kuroda, Junya
    Ishizawa, Kenichi
    Ichikawa, Satoshi
    Ando, Kiyoshi
    Ogura, Michinori
    Tobinai, Kensei
    Fukushima, Koji
    Murayama, Kayoko
    ANNALS OF ONCOLOGY, 2021, 32 : S304 - S304
  • [30] Azacytidine plus rituximab-gemcitabine-oxaliplatin as salvage treatment in patients with relapsed/ refractory diffuse large B-cell lymphoma
    Meng Fanqiao
    Xiang Maoyuan
    Peng Cuicui
    Liu Yu
    Zeng Dongfeng
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S453 - S453
12345